Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky
11:30am, Thursday, 20'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:00am, Thursday, 20'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceutical
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Re
NEW YORK , Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN du
Shareholders that Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky about Pending Class Action - REGN
05:15pm, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between N
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman
03:56pm, Wednesday, 19'th Feb 2025
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges,
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – REGN
12:15pm, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceutical
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
10:30am, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
10:00am, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:R
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
07:25am, Wednesday, 19'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
